Front. Oncol.
Frontiers in Oncology
Front. Oncol.
2234-943X
Frontiers Media S.A.
10.3389/fonc.2023.1339187
Oncology
Erratum
Erratum: PDGF, NGF, and EGF as main contributors to tumorigenesis in high-risk retinoblastoma
Frontiers Production Office
*
Frontiers Media SA, Lausanne, Switzerland
Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland
*Correspondence: Frontiers Production Office, production.office@frontiersin.org
07
12
2023
2023
13
1339187
15
11
2023
15
11
2023
Copyright © 2023 Frontiers Production Office
2023
Frontiers Production Office
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
An Erratum on PDGF, NGF, and EGF as main contributors to tumorigenesis in high-risk retinoblastoma By Al-Ghazzawi K, Wessolly M, Dalbah S, Ketteler P, Kiefer T, Bechrakis N, Leyla J, Ting S, Biewald E and Mairinger FD (2023) Front. Oncol. 13:1144951. doi: 10.3389/fonc.2023.1144951
retinoblastoma - epigenetics
retinoblastoma
PDGF = platelet-derived growth factor
MAPK/ERK2 pathway 1
pediatric cancer and oncology
biomarkers
targeted therapy
growth factors (angiogenesis factors)
section-in-acceptance
Pediatric Oncology
Due to a production error, section 3.2 Anaplastic grade included two empty subsections: 3.2.1 Undifferentiated retinoblastoma and 3.2.2 Differentiated retinoblastoma. These subsections have been removed.
The publisher apologizes for this mistake. The original version of this article has been updated.